Replimune Group, Inc. (NASDAQ:REPL) Given Average Rating of "Buy" by Brokerages

Shares of Replimune Group, Inc. (NASDAQ:REPL - Get Free Report) have received an average rating of "Buy" from the six ratings firms that are covering the company, Marketbeat.com reports. Five investment analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $16.80.

A number of research firms recently commented on REPL. JPMorgan Chase & Co. increased their price objective on Replimune Group from $14.00 to $17.00 and gave the stock an "overweight" rating in a report on Tuesday, September 24th. HC Wainwright restated a "buy" rating and set a $17.00 price target on shares of Replimune Group in a research note on Monday, September 16th. Roth Capital upgraded shares of Replimune Group to a "strong-buy" rating in a report on Tuesday, August 27th. Finally, Roth Mkm assumed coverage on shares of Replimune Group in a report on Tuesday, August 27th. They issued a "buy" rating and a $17.00 price objective for the company.

Insider Buying and Selling

In related news, CFO Emily Luisa Hill sold 8,938 shares of the firm's stock in a transaction on Friday, August 16th. The shares were sold at an average price of $10.18, for a total value of $90,988.84. Following the transaction, the chief financial officer now directly owns 101,057 shares in the company, valued at approximately $1,028,760.26. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. 8.80% of the stock is owned by insiders.

Institutional Trading of Replimune Group

Hedge funds have recently added to or reduced their stakes in the business. Creative Planning raised its stake in Replimune Group by 28.7% during the 3rd quarter. Creative Planning now owns 21,047 shares of the company's stock valued at $231,000 after purchasing an additional 4,699 shares during the last quarter. SG Americas Securities LLC bought a new position in shares of Replimune Group during the 3rd quarter worth about $251,000. Point72 DIFC Ltd acquired a new position in shares of Replimune Group during the second quarter valued at about $57,000. Cubist Systematic Strategies LLC lifted its stake in shares of Replimune Group by 282.2% in the second quarter. Cubist Systematic Strategies LLC now owns 72,207 shares of the company's stock valued at $650,000 after buying an additional 53,313 shares during the period. Finally, Algert Global LLC lifted its stake in shares of Replimune Group by 5.4% in the second quarter. Algert Global LLC now owns 84,033 shares of the company's stock valued at $756,000 after buying an additional 4,340 shares during the period. Institutional investors own 92.53% of the company's stock.

Replimune Group Stock Up 1.9 %

Shares of NASDAQ REPL traded up $0.22 during mid-day trading on Friday, reaching $11.53. The company had a trading volume of 316,491 shares, compared to its average volume of 1,093,506. The company has a debt-to-equity ratio of 0.16, a quick ratio of 13.46 and a current ratio of 13.46. Replimune Group has a twelve month low of $4.92 and a twelve month high of $15.33. The stock's 50 day moving average is $10.78 and its 200-day moving average is $8.84. The stock has a market capitalization of $787.73 million, a PE ratio of -3.53 and a beta of 1.21.

Replimune Group (NASDAQ:REPL - Get Free Report) last issued its earnings results on Thursday, August 8th. The company reported ($0.78) earnings per share for the quarter, topping the consensus estimate of ($0.88) by $0.10. As a group, equities analysts anticipate that Replimune Group will post -3.11 earnings per share for the current fiscal year.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.